Omalizumab is effective in treating systemic mastocytosis in a nonatopic patient

Allergy. 2010 Jul;65(7):926-7. doi: 10.1111/j.1398-9995.2009.02259.x. Epub 2009 Nov 4.

Authors

J A Douglass¹, K Carroll, A Voskamp, P Bourke, A Wei, R E O'Hehir

Affiliation

¹ Department of Allergy, Immunology and Respiratory Medicine, The Alfred Hospital and Monash University, Melbourne, Victoria, Australia. J.Douglass@alfred.org.au

PMID: 19889117
DOI: 10.1111/j.1398-9995.2009.02259.x

No abstract available

Publication types

Case Reports

MeSH terms

Anaphylaxis / etiology
Anaphylaxis / prevention & control
Anti-Allergic Agents / therapeutic use*
Antibodies, Anti-Idiotypic
Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Humanized
Female
Heart Arrest / etiology
Humans
Hypersensitivity, Immediate / immunology
Mastocytosis, Systemic / complications
Mastocytosis, Systemic / drug therapy*
Mastocytosis, Systemic / physiopathology
Middle Aged
Omalizumab

Substances

Anti-Allergic Agents
Antibodies, Anti-Idiotypic
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Omalizumab